Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PAVM Stock Forecast 2026-2027
$9.84
Current Price
$61.54M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PAVM Price Targets
+5,082.9%
To High Target of $510.00
+2,572.8%
To Median Target of $263.00
+62.6%
To Low Target of $16.00
PAVM Price Momentum
-0.1%
1 Week Change
-8.0%
1 Month Change
-51.8%
1 Year Change
+48.4%
Year-to-Date Change
-65.4%
From 52W High of $28.44
+64.0%
From 52W Low of $6.00
📊 TOP ANALYST CALLS
Did PAVM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PAVmed is one of their latest high-conviction picks.
Latest PAVM Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PAVM has a bullish consensus with a median price target of $263.00 (ranging from $16.00 to $510.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $9.84, the median forecast implies a 2,572.8% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PAVM Analyst Ratings
2
Buy
0
Hold
0
Sell
PAVM Price Target Range
Low
$16.00
Average
$263.00
High
$510.00
Current: $9.84
Latest PAVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PAVM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 10, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $17.00 |
| Oct 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $20.00 |
| Jun 6, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $19.00 |
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $19.50 |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $19.00 |
| Sep 10, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $21.00 |
| Aug 18, 2023 | Cantor Fitzgerald | Ross Osborn | Neutral | Reiterates | $1.40 |
| Jan 20, 2023 | Cantor Fitzgerald | Ross Osborn | Neutral | Downgrade | $1.50 |
| Jan 18, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $1.50 |
| Aug 17, 2022 | Lake Street | Frank Takkinen | Buy | Maintains | $5.00 |
| Mar 30, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 5, 2020 | Ascendiant Capital | Buy | Initiates | $N/A | |
| Oct 13, 2020 | Lake Street | Buy | Initiates | $N/A | |
| Jun 28, 2018 | Maxim Group | Buy | Initiates | $N/A |
PAVmed Inc. (PAVM) Competitors
The following stocks are similar to PAVmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PAVmed Inc. (PAVM) Financial Data
PAVmed Inc. has a market capitalization of $61.54M with a P/E ratio of 0.1x. The company generates $71,000 in trailing twelve-month revenue with a 564.8% profit margin.
Revenue growth is +420.0% quarter-over-quarter, while maintaining an operating margin of -13,082.7% and return on equity of -32.3%.
Valuation Metrics
Market Cap
$61.54M
Enterprise Value
$87.81M
P/E Ratio
0.1x
PEG Ratio
0.0x
Price/Sales
822.5x
Growth & Margins
Revenue Growth (YoY)
+420.0%
Gross Margin
-63.5%
Operating Margin
-13,082.7%
Net Margin
+564.8%
EPS Growth
+420.0%
Financial Health
Cash/Price Ratio
+3.1%
Current Ratio
0.2x
Debt/Equity
59.9x
ROE
-32.3%
ROA
-39.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
PAVmed Inc. (PAVM) Business Model
About PAVmed Inc.
What They Do
Medical device company focused on innovative technologies.
Business Model
The company develops and commercializes minimally invasive medical solutions, generating revenue through a diverse portfolio of products in diagnostics, medical devices, and healthcare technologies. PAVmed operates subsidiaries like Lucid Diagnostics and Solys, which focus on specialized diagnostic and biomaterial solutions, respectively.
Additional Information
Headquartered in New York, PAVmed aims to significantly impact the medical device market by targeting high-growth segments and addressing unmet patient needs through rapid product advancement and technological innovation.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
39
CEO
Dr. Lishan Aklog M.D.
Country
United States
IPO Year
2016
Website
www.pavmed.comPAVmed Inc. (PAVM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
PAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio Relaunch
PAVmed taps industry veteran Joseph Virgilio to lead its device portfolio relaunch to boost growth, commercialization and long-term shareholder value.
Apr 07, 2026
By Zacks Equity Research
Analyst Blog
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mar 30, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
PAVmed appoints a medtech industry veteran to lead its medical device portfolio. Its subsidiary, Octeris, Inc., will focus on advancing newly licensed endoscopic esophageal imaging technology.
Why It Matters
The appointment of a medtech veteran signals potential growth and innovation for PAVmed, while the new subsidiary could enhance its competitive edge in advanced imaging technologies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed Inc. (PAVM) held its Q4 2025 earnings call, providing updates on financial performance and business strategies. Further details are available in the transcript.
Why It Matters
PAVmed Inc.'s Q4 2025 earnings call reveals financial performance and future projections, impacting stock valuation and investor sentiment based on growth potential and market strategy.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
PAVmed's upgrade to a Zacks Rank #2 signals increased confidence in its earnings potential, likely boosting investor sentiment and potentially driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
10 days ago
Quick Summary
PAVmed has strengthened its capital structure and relaunched its medical device portfolio. Veris Health advanced its partnership with OSU, while Lucid Diagnostics expanded its healthcare system access. A conference call is scheduled for March 30, 2026, at 8:30 AM EST.
Why It Matters
PAVmed's capital structure improvement, product relaunch, and partnerships may enhance growth prospects, affecting stock performance and investor sentiment positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed Inc. (PAVM) held a shareholder and analyst call, discussing key updates and financial performance. Details of the call are available in the prepared remarks transcript.
Why It Matters
The shareholder/analyst call may provide insights into PAVmed's financial performance, strategic direction, and potential growth, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
14 days ago
Quick Summary
Lucid Diagnostics reported 4Q25 revenue of $1.5 million from 3,664 EsoGuard tests. They secured a contract with the U.S. Department of Veterans Affairs and presented positive clinical data.
Why It Matters
Lucid Diagnostics' revenue growth and VA contract expansion indicate increased market traction and potential for future earnings, signaling positive momentum for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PAVM Stock
What is PAVmed Inc.'s (PAVM) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, PAVmed Inc. (PAVM) has a median price target of $263.00. The highest price target is $510.00 and the lowest is $16.00.
Is PAVM stock a good investment in 2026?
According to current analyst ratings, PAVM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PAVM stock?
Wall Street analysts predict PAVM stock could reach $263.00 in the next 12 months. This represents a 2,572.8% increase from the current price of $9.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is PAVmed Inc.'s business model?
The company develops and commercializes minimally invasive medical solutions, generating revenue through a diverse portfolio of products in diagnostics, medical devices, and healthcare technologies. PAVmed operates subsidiaries like Lucid Diagnostics and Solys, which focus on specialized diagnostic and biomaterial solutions, respectively.
What is the highest forecasted price for PAVM PAVmed Inc.?
The highest price target for PAVM is $510.00 from at , which represents a 5,082.9% increase from the current price of $9.84.
What is the lowest forecasted price for PAVM PAVmed Inc.?
The lowest price target for PAVM is $16.00 from at , which represents a 62.6% increase from the current price of $9.84.
What is the overall PAVM consensus from analysts for PAVmed Inc.?
The overall analyst consensus for PAVM is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $263.00.
How accurate are PAVM stock price projections?
Stock price projections, including those for PAVmed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 9, 2026 10:30 PM UTC